pharma · JBCHEPHARM
J B Chemicals
J B Chemicals: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹2,408.9
Price 2026-07-23
5 day
+0.00%
Short-term move
1 month
+7.68%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹38.9k Cr
inflow sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's NARROW LEADERSHIP regime affect J B Chemicals (JBCHEPHARM) in the pharma sector?”
Price chart
₹2,409
+44.96% over period
About J B Chemicals
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is head...
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -7.6% over 14 days) — not a reliable pattern.
52-week position
Trading at 99.2% of 52-week high
Technicals
RSI 14
58.6
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
54.5
71th pct · 7 quarterly points (limited history)
P/B
9.3
ROE
18.7%
Moderate profitability — 18.7% ROE
Market cap
₹38.9k Cr
Revenue growth
-480.0% YoY
Promoter
49.2%
52-week range
₹1,603.5 – ₹2,428.8
99.2% of high
RSI (14)
58.6
uptrend
vs 50 DMA
Above
DMA ₹2,267.94
Coverage
100/100
HIGH
Quick Take
J B Chemicals: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹7,835 | +7.7% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,466.4 | +5.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,144.8 | -1.8% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,576.3 | +3.5% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
| ALKEM Alkem Laboratories | ₹5,816.5 | +3.8% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹425.35 | -2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,190.3 | -0.7% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,517 | +5.9% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| JBCHEPHARM J B Chemicals | ₹2,408.9 | +0.0% | 54.5 | 18.7% | -480% | ₹38.9k Cr |
Tensions to watch
Promoter holding at 49.2% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹2529 (+5%)
Trend reversal confirmation
Breaks below ₹2288 (-5%)
Further downside risk
PE reverts to median of 43.8 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing